Idexx Laboratories (IDXX)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
$575.98+2.32%
Close 2026-10-29 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
Research Workspace
Put IDXX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 13% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 12%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskHealthy across the board
IDXX’s CAG Diagnostics recurring revenue engine must keep growing to support its premium valuation. Revenue growth slowed to 10% in Q2 FY2026 from 14% in the prior two quarters. Q2 FY2026 revenue growth accompanied a non-GAAP earnings beat. IDXX trades at 41× P/E versus a 30× peer median, despite matching its 41× historical multiple. The price reflects less growth than our forecast. Our model puts the next-quarter miss probability near 17%. Peer multiples imply a price about 20% below where it trades; our read remains intact, and this read is provisional.
Trailing returns as of 2026-10-29. IDXX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering IDXX (as of Oct 2026).
Based on 3 Wall Street analysts offering 12-month price targets for IDXX in the last 4 months.
Continue this research
Compare IDXX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| IDXX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put IDXX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
IDEXX's acquisition of CoVetAI is a confirmed strategic transaction, but no thesis-level financial impact is stated.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $575.98
The last 12 months of price, then the range of analyst 12-month targets from today’s $575.98.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Expand CAG Diagnostics recurring revenue
Highlights in diagnostics enhance recurring revenue potential.
Advances: Expand CAG Diagnostics recurring revenue
AI scribe enhances CAG Diagnostics sales potential.
Advances: Expand CAG Diagnostics recurring revenue
Acquisition enhances CAG Diagnostics recurring revenue potential.
Advances: Expand CAG Diagnostics recurring revenue
Diagnostics growth aligns with expanding CAG Diagnostics revenue.
Advances: Expand CAG Diagnostics recurring revenue
AI and cancer tests enhance recurring revenue potential.
Strong Q2 results support revenue and EPS growth objectives.
Advances: Increase 2026 revenue guidance
Earnings beat supports increased revenue guidance.